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Gene mutations represent a major driving force in the onset and
progression of melanoma. Consequently many genes are being
investigated for their role in melanomagenesis, including not only
inherited genes but also genetic defects that are acquired due to
environmental factors, such as excessive sun exposure. The field of
melanoma genetics thus encompasses genes in familial melanoma
through to non-inherited genes that increase risk of melanoma.
Melanoma genomics on the other hand is the study of genomes of
melanoma cells and other cell types and their role in melanoma
onset and progression. A “genome” includes not only all the genes
of a cell, but also any genetic factors involved in programing the
cell and its function.
The present volume aims to provide the reader with a snap-
shot of current genetic and genomic investigations of melanoma,
with special emphasis on targeted treatments, and personalized
medicine. A collection of Opinion, Review, Primary Research,
Hypothesis and Theory, and Methods articles has been assem-
bled that describes the panoply of genes, therapeutic targets, bio-
markers, genetic pathways, and pathogenic mechanisms involved
in melanoma onset and metastasis, and of clinical outcomes
in patient in response to chemotherapy, immunotherapy, and
personalized treatment options.
Much progress has been made in identifying individual genes
and pathways involved in melanomagenesis, as outlined in the
Review Article by Wangari-Talbot and Chen (1). Indeed, the dis-
covery that melanomas frequently contain somatically acquired
mutations in the BRAF gene that drive melanoma growth has
revolutionized melanoma treatment options, and led to the devel-
opment of personalized targeted treatments for patients with
metastatic melanomas bearing a BRAF mutation, reviewed by
Klinac et al. (2).
Despite melanomas harboring somatically acquired mutations
in genes likeBRAF orNRAS, the response of individual melanoma
patients to BRAF inhibitor treatments is very variable, and Stones
et al. (3) have investigated gene mutation status with respect to
sensitivity to BRAF inhibitors and combination targeted therapies
in a panel of New Zealand human melanoma cell lines in their
Original Research Article.
Mutations in genes like GNAQ, GNA11, and BAP1 are asso-
ciated with uveal melanoma or blue nevi, and for the first time
Hawkes et al. (4) have investigated in their Original Research Arti-
cle whether inherited mutations in these genes are associated with
familial predisposition to uveal melanoma or blue nevi.
Although BRAF mutations can be identified from the very ear-
liest stages of melanoma onset, targeted BRAF inhibitor therapies
are presently validated for use in advanced stage IV melanomas.
Could therapies targetingBRAF be successfully used to treat earlier
stages of melanoma? This is the subject of an Opinion Article by
Ahn and Eccles (5).
With the plethora of genomic information, treatments, and
outcome data available from melanoma studies, what is the best
way to manage and interrogate all of this burgeoning infor-
mation? Trevarton et al. (6) describe a web tool integrating
multiple sources of genomic information called MelanomaDB
in their Methods Article. Then immediately following this is a
critique by Reinhold (7) of the advantages and disadvantages
of the approach taken by the MelanomaDB article for data
integration.
In addition to “driver” mutations in BRAF, and the related
growth promoting pathways, other pathways are also very likely
to be important in melanoma metastasis, including the Hippo
pathway, which is discussed in the Hypothesis and Theory Article
by Kim et al. (8).
An Original Research Article by Kim et al. (9) investigates
the role of epithelial-mesenchymal transition marker expression
in human melanocytes and melanoma cell lines. In a simi-
larly themed article Eccles et al. (10) suggest that switching of
melanoma cells from a proliferative to an invasive phenotype
during metastasis has parallels with developmental mechanisms,
which could be under genetic control. They propose a genetic
switch theory, which they hypothesize is involved in the transition
of melanoma cells to an invasive phenotype in their Hypothesis
and Theory Article.
Biomarkers of melanoma progression and metastasis are
expected to help with further stratification of patients with poor
prognosis following melanoma diagnosis, as discussed by Dye
et al. (11) in their Review Article. Expression of one factor called
GLIPR1 was found to correlate with the invasive potential in
melanoma cells, as demonstrated in an Original Research Article
by Awasthi et al (12).
Metastasis generally involves the dissemination of circulating
melanoma cells, as discussed in an Opinion Article by Joshi et al.
(13), but frequently melanomas metastasize to the brain, which is
discussed in an Opinion Article by Yashin et al. (14). The poten-
tial for targeted therapy of melanoma brain metastasis through
in vivo modeling and molecular characterization is the subject of
a Review Article by Gaziel-Sovran et al. (15).
This collection of articles clearly demonstrates the impact that
melanoma genetics and genomics has had on targeted treatments
and improved outcomes of melanoma patients in the past decade,
and of the promise yet to come, but melanoma remains an impor-
tant public health issue in Western societies. This is especially so
www.frontiersin.org December 2013 | Volume 3 | Article 309 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eccles Melanoma genetics/genomics
in New Zealand and Australia, where the recorded incidence rates
are the highest in the world (41.2 per 100,000 population in New
Zealand, age standardized to the Segi world population, 2004, and
37.2 per 100,000 in Australia, as compared to, for example, 11.9
per 100,000 in Western Europe. Clearly much work still needs to
be done to address these high incidence and mortality rates of
melanoma.
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